Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

Launched by BRISTOL-MYERS SQUIBB · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Exclusion Criteria
• Co-existing Condition:
• • Patients with histological or clinical (skin rash, cotton wool exudates, Candida endophthalmitis, etc.) evidence of disseminated candidiasis are excluded.
• Concurrent Medication:
• Excluded:
• • Systemic administration of amphotericin B for a proven or suspected systemic fungal infection.
• Patients with the following are excluded:
• • Documented Candida fungemia.
• • Histological or clinical (skin rash, cotton wool exudates, Candida endophthalmitis, etc.) evidence of disseminated candidiasis.
• • Systemic administration of amphotericin B for a proven or suspected systemic fungal infection.
• • Patient refusal to enter study.
• • Patient must be an immunosuppressed host, with biopsy-proven Candida esophagitis.
• • Patients with polymicrobial esophagitis will be included as long as Candida esophagitis is documented by esophageal biopsy.
• • Informed consent must be signed and obtained.